Theravance Biopharma(TBPH) ZACKS·2024-11-13 00:10Core Insights - Theravance Biopharma reported a quarterly loss of 0.10, representing a 40% earnings surprise [1] - The company generated revenues of 15.69 million year-over-year [2] - The stock has underperformed, losing approximately 19.2% since the beginning of the year, while the S&P 500 has gained 25.8% [3] Financial Performance - Over the last four quarters, Theravance Biopharma has surpassed consensus EPS estimates three times and topped revenue estimates two times [2] - The current consensus EPS estimate for the upcoming quarter is -34.22 million, and for the current fiscal year, it is -79.17 million [7] Market Outlook - The Zacks Rank for Theravance Biopharma is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] - The Medical - Drugs industry, to which Theravance belongs, is currently in the top 27% of Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]